C. Lorentzen

Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement.

R. Neitz, H. Sham, T. Yednock, 2011, Bioorganic & medicinal chemistry letters.

Novel cinnoline-based inhibitors of LRRK2 kinase activity.

R. Neitz, M. Adler, H. Sham, 2013, Bioorganic & medicinal chemistry letters.

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration.

G. Tóth, H. Sham, N. Yao, 2011, Bioorganic & medicinal chemistry letters.

Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.

John-Michael Sauer, Zhao Ren, Dean R Artis, 2011, Bioorganic & medicinal chemistry letters.

LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial

I. Svane, M. Andersen, E. Martinenaite, 2020 .

Novel cinnoline-based inhibitors of LRRK2 kinase activity.

M. Adler, H. Sham, M. Franzini, 2013, Bioorganic & medicinal chemistry letters.